Besonprodil

Besonprodil

Clinical data
Other names	CI-1041
ATC code	None
Identifiers
IUPAC name 6-[2-(4-[(4-fluorophenyl)methyl]piperidin-1-yl)ethylsulfinyl]-3H-1,3-benzoxazol-2-one
CAS Number	253450-09-8 N
PubChem CID	156328
ChemSpider	137662 Y
UNII	5K3N2D15WW
ChEMBL	ChEMBL219631 Y
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H23FN2O3S
Molar mass	402.48 g·mol−1
3D model (JSmol)	Interactive image
SMILES c4cc(F)ccc4CC(CC2)CCN2CCS(=O)c(cc1o3)ccc1[nH]c3=O
InChI InChI=1S/C21H23FN2O3S/c22-17-3-1-15(2-4-17)13-16-7-9-24(10-8-16)11-12-28(26)18-5-6-19-20(14-18)27-21(25)23-19/h1-6,14,16H,7-13H2,(H,23,25) Y Key:FCBQJNCAKZSIAH-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Besonprodil (CI-1041) is a drug which acts as an NMDA antagonist, selective for the NR2B subunit. It is under development as a supplemental medication for Parkinson's disease, and has been shown in animals to be effective in counteracting the dyskinesias associated with long-term treatment with levodopa and related drugs.